FAS and central nervous system cancer: It is known that expression of the cell death receptor FAS is heterogeneous in glioma, and glioma cell lines may differ in sensitivity to FASL-mediated cell death [41, 42] due to low surface FAS expression or due to the expression of apoptosis-regulating genes.